Quick Answer
Cardlytics, Inc. reported Cash and Equivalents of $48.72 million for fiscal year 2025.
Cardlytics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $48.72M | -25.7% |
| 2024 | $65.59M | -28.6% |
| 2023 | $91.83M | -24.7% |
| 2022 | $121.91M | -47.8% |
| 2021 | $233.47M | -20.4% |
| 2020 | $293.24M | +180.7% |
| 2019 | $104.46M | +163.6% |
| 2018 | $39.62M | +86.4% |
| 2017 | $21.26M | -46.3% |
| 2017 | $39.62M | +73.5% |
| 2016 | $22.84M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.96M | -34.4% | -6.0% |
| June 30, 2025 | $46.74M | -34.4% | -10.2% |
| March 31, 2025 | $52.05M | -46.8% | -20.7% |
| December 31, 2024 | $65.59M | -28.6% | -2.1% |
| September 30, 2024 | $66.99M | -25.6% | -6.0% |
| June 30, 2024 | $71.25M | -22.6% | -27.1% |
| March 31, 2024 | $97.77M | -29.8% | +6.5% |
| December 31, 2023 | $91.83M | -24.7% | +2.0% |
- Cardlytics, Inc. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Cardlytics, Inc.’s cash and equivalents has grown by 113.3% (from $22.84 million to $48.72 million).
- The most recent figure is from Cardlytics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: